Navigation Links
What is the more suitable for early detection of low abundant lamivudine-resistant mutants?
Date:1/16/2008

Lamivudine is an effective antiviral agent for treatment of patients with chronic hepatitis B and advanced liver diseases. However, long-term lamivudine monotherapy leads to the emergence of lamivudine-resistant hepatitis B virus (HBV) mutants in some patients chronically infected with HBV. Sensitive methods for early detection of lamivudine-resistant mutants will help physicians make clinical decisions in treating patients with HBV infection.

To date, many assays have been used for detection of lamivudine-resistant mutants in patients with Hepatitis B. Differences in sensitivity, specificity, cost, and time required, exist in these methods. Real-time PCR is able to quantitatively detect a small portion of resistant mutants in HBV populations and ligase detection reaction (LDR) is a newly developed method for detection of low abundant mutants in the background of wild-type HBV. However, there are no studies which have compared the clinical performance of the two methods.

A research article to be published on January 7 in the World Journal of Gastroenterology (volume 14, issue 1) addresses this question. It compared LDR and real-time PCR for detection of low abundant YMDD mutations in mixed plasmids and serum samples from 52 lamivudine treated patients. Time required and reagent cost for both assays were evaluated. The research was conducted carefully by an experienced team of investigators.

The article suggested both methods are sensitive and inexpensive for detection of YMDD mutation; but LDR is more sensitive than real-time PCR. The results obtained with both methods were completely concordant in all serum samples. LDR was able to detect as low as 0.01% (100 copies/mL) of YIDD plasmid, while real-time PCR only detected 0.1% (1000 copies/mL) of YIDD plasmid in the background of YMDD plasmid. In addition, the cost of LDR is slightly lower than that of real-time PCR.

However, real-time PCR is much more rapid and requires le
'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Research suggests new treatment suitable for all patients
2. Pot bellies linked to early signs of cardiovascular disease
3. Eye-staining technique offers early detection for dry eye syndrome
4. Early Weight Loss in Women Linked to Dementia
5. Isolation of a new gene family essential for early development
6. U of M study: Early treatment can reverse heart damage
7. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
8. Rock N Roll: Sex, Drugs and an Early Exit
9. Pop stars more than twice as likely to die an early death
10. Exercise and yoga improves quality of life in women with early-stage breast cancer
11. Research says doctors gender may hinder early diagnosis of heart disease in women
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Confusion Over Homeopathic Medicines in Alexa Ray Joel's Hospitalization Clarified by the American Association of Homeopathic Pharmacists (AAHP) 2DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 1DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 2DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 3DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 4DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 5DOR BioPharma Announces Publication of orBec 28R 29 Clinical Pulmonary Data in Bone Marrow Transplantation 12820 6Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 1Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 2Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 3YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 1YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 2YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 3YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 12817 4